Caitlin John’s Tiziana Life Sciences TLSA Stock Holding History

Caitlin John’s Portfolio TLSA Stock Details TLSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,500	Closed	-$7.56K	–	1003
2025 Q3	$7.56K	Sell	3,500 -6,500	-65%	-$12K	0.01%	535
2025 Q2	$15.8K	Buy	+10,000	New	+$13.4K	0.01%	133
2025 Q1	–	Sell	-3,000	Closed	-$2.09K	–	736
2024 Q4	$2.09K	Hold	3,000	–	–	﹤0.01%	657
2024 Q3	$2.71K	Buy	+3,000	New	+$3.03K	﹤0.01%	623

Other funds holding TLSA

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Zhang Financial Portage, Michigan $2.89B AUM 18.44% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caitlin John's TLSA Position: Q4 2025 in Review

Caitlin John sold out of Tiziana Life Sciences (TLSA) in Q4 2025, closing a stake of 3,500 shares — an estimated $7.56K sold.

Caitlin John first reported a position in TLSA in Q3 2024 and held it in 4 quarters. The position peaked at $15.8K in Q2 2025. 33 funds tracked by Wall St. Rank hold TLSA as of Q4 2025.

Caitlin John reported no remaining Tiziana Life Sciences position as of Q4 2025 after selling out during the quarter.
Caitlin John sold 3,500 Tiziana Life Sciences shares in Q4 2025, an estimated $7.56K.
Caitlin John first reported a position in Tiziana Life Sciences in Q3 2024 and held it in 4 quarters.
Caitlin John's Tiziana Life Sciences position peaked at $15.8K in Q2 2025.
33 funds tracked by Wall St. Rank held Tiziana Life Sciences as of Q4 2025.

Based on Caitlin John's 13F filing for Q4 2025, filed 18 Feb 2026.